192 related articles for article (PubMed ID: 19022363)
1. Pharmacogenomic approaches in clinical studies to identify biomarkers of safety and efficacy.
Burczynski ME
Toxicol Lett; 2009 Apr; 186(1):18-21. PubMed ID: 19022363
[TBL] [Abstract][Full Text] [Related]
2. Toxicogenomics in predictive toxicology in drug development.
Suter L; Babiss LE; Wheeldon EB
Chem Biol; 2004 Feb; 11(2):161-71. PubMed ID: 15123278
[TBL] [Abstract][Full Text] [Related]
3. An FDA perspective on the nonclinical use of the X-Omics technologies and the safety of new drugs.
Jacobs A
Toxicol Lett; 2009 Apr; 186(1):32-5. PubMed ID: 18809476
[TBL] [Abstract][Full Text] [Related]
4. Toxicogenomics in drug discovery: from preclinical studies to clinical trials.
Yang Y; Blomme EA; Waring JF
Chem Biol Interact; 2004 Nov; 150(1):71-85. PubMed ID: 15522262
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers: a valuable tool in clinical research and medical practice.
Carini C
IDrugs; 2007 Jun; 10(6):395-8. PubMed ID: 17642003
[TBL] [Abstract][Full Text] [Related]
6. Strategic applications of toxicogenomics in early drug discovery.
Ryan TP; Stevens JL; Thomas CE
Curr Opin Pharmacol; 2008 Oct; 8(5):654-60. PubMed ID: 18760379
[TBL] [Abstract][Full Text] [Related]
7. The Japanese toxicogenomics project: application of toxicogenomics.
Uehara T; Ono A; Maruyama T; Kato I; Yamada H; Ohno Y; Urushidani T
Mol Nutr Food Res; 2010 Feb; 54(2):218-27. PubMed ID: 20041446
[TBL] [Abstract][Full Text] [Related]
8. Toxicogenomics and clinical toxicology: an example of the connection between basic and applied sciences.
Ferrer-Dufol A; Menao-Guillen S
Toxicol Lett; 2009 Apr; 186(1):2-8. PubMed ID: 19027838
[TBL] [Abstract][Full Text] [Related]
9. A holistic strategy for characterizing the safety of metabolites through drug discovery and development.
Walker D; Brady J; Dalvie D; Davis J; Dowty M; Duncan JN; Nedderman A; Obach RS; Wright P
Chem Res Toxicol; 2009 Oct; 22(10):1653-62. PubMed ID: 19715349
[TBL] [Abstract][Full Text] [Related]
10. The state-of-the-art in predictive toxicogenomics.
Fielden MR; Kolaja KL
Curr Opin Drug Discov Devel; 2006 Jan; 9(1):84-91. PubMed ID: 16445120
[TBL] [Abstract][Full Text] [Related]
11. Toxicogenomics in the pharmaceutical industry: hollow promises or real benefit?
Lühe A; Suter L; Ruepp S; Singer T; Weiser T; Albertini S
Mutat Res; 2005 Aug; 575(1-2):102-15. PubMed ID: 15924886
[TBL] [Abstract][Full Text] [Related]
12. Identification of genomic biomarkers for concurrent diagnosis of drug-induced renal tubular injury using a large-scale toxicogenomics database.
Kondo C; Minowa Y; Uehara T; Okuno Y; Nakatsu N; Ono A; Maruyama T; Kato I; Yamate J; Yamada H; Ohno Y; Urushidani T
Toxicology; 2009 Nov; 265(1-2):15-26. PubMed ID: 19761811
[TBL] [Abstract][Full Text] [Related]
13. Toxicogenomics: a pivotal piece in the puzzle of toxicological research.
Gatzidou ET; Zira AN; Theocharis SE
J Appl Toxicol; 2007; 27(4):302-9. PubMed ID: 17429800
[TBL] [Abstract][Full Text] [Related]
14. Novel biomarkers of acute kidney toxicity.
Goodsaid FM; Blank M; Dieterle F; Harlow P; Hausner E; Sistare F; Thompson A; Vonderscher J
Clin Pharmacol Ther; 2009 Nov; 86(5):490-6. PubMed ID: 19710639
[TBL] [Abstract][Full Text] [Related]
15. Emerging applications of kinetic biomarkers in preclinical and clinical drug development.
Turner SM; Hellerstein MK
Curr Opin Drug Discov Devel; 2005 Jan; 8(1):115-26. PubMed ID: 15679179
[TBL] [Abstract][Full Text] [Related]
16. Genomic and genetic biomarkers of toxicity.
Mendrick DL
Toxicology; 2008 Mar; 245(3):175-81. PubMed ID: 18206287
[TBL] [Abstract][Full Text] [Related]
17. Integrated strategies for assessment of metabolite exposure in humans during drug development: analytical challenges and clinical development considerations.
Zhu M; Zhang D; Zhang H; Shyu WC
Biopharm Drug Dispos; 2009 May; 30(4):163-84. PubMed ID: 19544287
[TBL] [Abstract][Full Text] [Related]
18. Serum chemical biomarkers of cardiac injury for nonclinical safety testing.
Walker DB
Toxicol Pathol; 2006; 34(1):94-104. PubMed ID: 16507550
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers in aquatic plants: selection and utility.
Brain RA; Cedergreen N
Rev Environ Contam Toxicol; 2009; 198():49-109. PubMed ID: 19253039
[TBL] [Abstract][Full Text] [Related]
20. A strategic view on the use of pharmacodynamic biomarkers in early clinical drug development.
Severino ME; Dubose RF; Patterson SD
IDrugs; 2006 Dec; 9(12):849-53. PubMed ID: 17139572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
